Medulloblastoma, SHH-Activated, TP53-Mutant — Variants & evidence

Medulloblastoma, SHH-Activated, TP53-Mutant — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TP53 Mutation3
(predisposing)	Predisposing	B	Supports Predisposition	5	submitted	EID8346 This international, multicenter study analyzed patients with medulloblastoma (MB) from both retrospective and prospective cohorts in order to identify consensus MB predisposition genes. A total of 102… (full text at CIViC) PMID 29753700 · Waszak et al., 2018 · Open in CIViC	civic
(diagnostic)	Diagnostic	B	Supports Positive	4	submitted	EID8345 One of the goals of this study is to understand the biology of the sonic-hedgehog subgroup of medulloblastoma (SHH-MB) across different age groups. A large cohort of patients (n=133) with SHH-MB, incl… (full text at CIViC) PMID 24651015 · Kool et al., 2014 · Open in CIViC	civic
Vismodegib	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID8348 Two phase II studies (PBTC-025B, n=31, age ≥ 22 years; PBTC-032, n=12, age 3-21 years) assessed the targeted efficacy of vismodegib, an SMO inhibitor, in patients with recurrent sonic hedgehog subgrou… (full text at CIViC) PMID 26169613 · Robinson et al., 2015 · Open in CIViC	civic

Data updated 15 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.